{"name":"Shanghai AbelZeta Ltd.","slug":"shanghai-abelzeta-ltd","ticker":"","exchange":"","domain":"shanghaiabelzeta.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Mesenchymal stem cells low-dose group","genericName":"Mesenchymal stem cells low-dose group","slug":"mesenchymal-stem-cells-low-dose-group","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Mesenchymal stem cells low-dose group","genericName":"Mesenchymal stem cells low-dose group","slug":"mesenchymal-stem-cells-low-dose-group","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxQUmFNdHpGemtVcHBNTlRjaDlVOVRYRWJBUjlXTUExV0diMi1xckxsZ2x0b2czdE51dEktU21pbHp4Y1QxeFlHMlRINDhsNnpFbEtTYXBMS1BCemEzTmtoOExrYWw3XzVBZWhrajJ3RkZublhabzlBSnBUN2plbExfZG1yOFFTUFVpQTFIb2M5SkJfbmhJQzhjNnhGMU1kY00ydTdMdFlzazF5SHBZM0pKank4VlBwVnY5OVUyTEpCMktPQWtLR3BTWnJ6THpqQWJxM00xdGlGZDVmaGU5S2JsOVZ1a1E5M0xCM3A0YTB3?oc=5","date":"2026-01-18","type":"regulatory","source":"PR Newswire","summary":"AbelZeta Announces Remaining China Rights to GPC3 Armored CAR-T Therapy to be Acquired by AstraZeneca - PR Newswire","headline":"AbelZeta Announces Remaining China Rights to GPC3 Armored CAR-T Therapy to be Acquired by AstraZeneca","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxQUDZMRUlwY1A3T0hBcDBLR2xhOVBNd0p4d1cwSEJVaTVtdE5RTHAxYXhVaXJURTZYeHFmM0lueGZKc3JDbUxfbWp1VmUxRk8zREhzTlZvUnFOU2xZOURvWmQ1SzdFTm05NHRub0RlSzNqcWpHUUJ0eHY5d3paZ2JTWktTX2pHaHJmV01ONUFQbjc4Y1hpbmM5QmRSN1lZOXVXWlktNXNENExuRFBxajZINnB0a01rSHZ1cndvOWRCVHVWNXVxWUxjSWNSY29uelJiZ2FxY0hQbzMwcFMydFoyX0VURi1weG83WXBhak9Xb1dPcEF5MUE?oc=5","date":"2023-12-14","type":"deal","source":"PR Newswire","summary":"AbelZeta Announces Amendment to Worldwide Collaboration and License Agreement with Janssen to Include China - PR Newswire","headline":"AbelZeta Announces Amendment to Worldwide Collaboration and License Agreement with Janssen to Include China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3wFBVV95cUxQWGFVcEhtNV9vdTRfeklQbEFrR19VeFNMb2tOSnNxVWtlcEc0VzJTUkRMbVoyNlBZbnJuR1BJdFliY3lpZUVZdzU5V3FZZXRkendSRzlvU3JRZ1pGNGlYVFRITFJiamhOb1ZPZE0zR2dkdjBIdFV4Zi1WOWNUV2thdXZJUnJ4ZTdSaFdRTEJxVFNCcVo2Ymx6X1BHeG1WTnh6TWRRQTJSWkdfMFNUazd2bG44V0JhNERxcVNUWGxEVmJTNjZUdzR5Z3JIUGx6cnhSV1U3S3AwTTd0LWhrQ2xB?oc=5","date":"2023-12-07","type":"pipeline","source":"BioSpace","summary":"AbelZeta Pharma Announces Agreement with AstraZeneca to Co-Develop a novel Glypican 3 (GPC3) Armored CAR-T Therapy in China - BioSpace","headline":"AbelZeta Pharma Announces Agreement with AstraZeneca to Co-Develop a novel Glypican 3 (GPC3) Armored CAR-T Therapy in Ch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQRHNvLVIwYVF6YlRVS1NXOFBfeGtSVG9Ec0o5c3YzOGZwN1lLSVRvb0NMOXZZc3EwY0ZfNUc5Z1pLb19kZmxMUkhJSGdYTEFiZWV0Z3lWMUp1ZU1yMm4tN1kxZHpXd1FaZXZCb3hSbUkwa2J5N2ZfckU1bTBHZU5RSlJJUTg4ajRjakNJ?oc=5","date":"2023-11-20","type":"pipeline","source":"BioSpace","summary":"CBMG Holdings Announces Name Change to AbelZeta Pharma, Inc. - BioSpace","headline":"CBMG Holdings Announces Name Change to AbelZeta Pharma, Inc.","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}